Jefferies Financial Group Inc. acquired a new position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 647,391 shares of the company's stock, valued at approximately $15,440,000. Jefferies Financial Group Inc. owned approximately 2.12% of Castle Biosciences as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also bought and sold shares of the company. Truist Financial Corp boosted its holdings in shares of Castle Biosciences by 1.1% during the 4th quarter. Truist Financial Corp now owns 23,628 shares of the company's stock valued at $919,000 after acquiring an additional 257 shares during the last quarter. CWM LLC raised its holdings in shares of Castle Biosciences by 20.5% during the fourth quarter. CWM LLC now owns 2,302 shares of the company's stock valued at $90,000 after purchasing an additional 391 shares during the last quarter. HRT Financial LP lifted its position in Castle Biosciences by 0.9% during the fourth quarter. HRT Financial LP now owns 47,654 shares of the company's stock valued at $1,853,000 after purchasing an additional 415 shares during the period. Assetmark Inc. lifted its position in Castle Biosciences by 9.3% during the first quarter. Assetmark Inc. now owns 5,779 shares of the company's stock valued at $142,000 after purchasing an additional 492 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in Castle Biosciences by 0.5% in the third quarter. Franklin Resources Inc. now owns 99,787 shares of the company's stock worth $2,272,000 after purchasing an additional 540 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have commented on CSTL. Weiss Ratings raised shares of Castle Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, July 31st. BTIG Research raised their price target on Castle Biosciences from $40.00 to $44.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Roth Capital began coverage on Castle Biosciences in a report on Wednesday, June 24th. They issued a "buy" rating and a $40.00 price objective for the company. Wall Street Zen upgraded Castle Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, August 1st. Finally, KeyCorp set a $35.00 target price on Castle Biosciences in a report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.00.
Check Out Our Latest Report on Castle Biosciences
Insider Activity
In related news, insider Derek J. Maetzold sold 20,356 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $31.11, for a total transaction of $633,275.16. Following the completion of the transaction, the insider directly owned 21,479 shares in the company, valued at approximately $668,211.69. The trade was a 48.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Tobin W. Juvenal sold 17,310 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $29.31, for a total transaction of $507,356.10. Following the completion of the sale, the insider directly owned 80,725 shares of the company's stock, valued at $2,366,049.75. This represents a 17.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 169,957 shares of company stock valued at $4,996,708 in the last ninety days. Corporate insiders own 6.10% of the company's stock.
Castle Biosciences Price Performance
NASDAQ CSTL opened at $34.26 on Friday. The company has a market capitalization of $1.05 billion, a PE ratio of -51.91 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. The business's fifty day moving average is $26.99 and its 200 day moving average is $25.42. Castle Biosciences, Inc. has a fifty-two week low of $17.72 and a fifty-two week high of $44.28.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.34. The business had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Sell-side analysts predict that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.
Castle Biosciences Company Profile
(
Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Featured Articles
Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
